Role of rasagiline in treating Parkinson’s disease: effect on disease progression
Irene A Malaty, Hubert H FernandezUniversity of Florida Movement Disorders Center, Gainesville, FL, USAAbstract: Rasagiline is a second generation, selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It has demonstrated efficacy in monotherapy for early Parkinson’s dise...
Main Authors: | Irene A Malaty, Hubert H Fernandez |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-05-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/role-of-rasagiline-in-treating-parkinsonrsquos-disease-effect-on-disea-a3160 |
Similar Items
-
Rasagiline in treatment of Parkinson’s disease
by: Lakshmi Nayak, et al.
Published: (2008-03-01) -
The role of rasagiline in the treatment of Parkinson’s disease
by: Julie Leegwater-Kim, et al.
Published: (2010-05-01) -
Adjunctive therapy in Parkinson's disease: the role of rasagiline
by: Gaines KD, et al.
Published: (2012-07-01) -
Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
by: Schettino C, et al.
Published: (2016-09-01) -
From a Parkinson's disease expert: Rasagiline and the Future of Therapy
by: Lakhan Shaheen E
Published: (2007-07-01)